Table of Contents

1 Study Coverage

• 1.1 Alzheimer’s Therapeutic Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Alzheimer’s Therapeutic Market Size Growth Rate by Product
  • 1.4.2 Memantine Hydrochloride
  • 1.4.3 Donepezil Hydrochloride
  • 1.4.4 Rivastigmine
  • 1.4.5 Galantamine Hydrobromide
• 1.5 Market by End User
  • 1.5.1 Global Alzheimer’s Therapeutic Market Size Growth Rate by End User
  • 1.5.2 Hospitals
  • 1.5.3 Clinic
  • 1.5.4 Other
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Alzheimer’s Therapeutic Market Size
  • 2.1.1 Global Alzheimer’s Therapeutic Revenue 2014-2025
  • 2.1.2 Global Alzheimer’s Therapeutic Sales 2014-2025
• 2.2 Alzheimer’s Therapeutic Growth Rate by Regions
  • 2.2.1 Global Alzheimer’s Therapeutic Sales by Regions
  • 2.2.2 Global Alzheimer’s Therapeutic Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Alzheimer’s Therapeutic Sales by Manufacturers
  • 3.1.1 Alzheimer’s Therapeutic Sales by Manufacturers
  • 3.1.2 Alzheimer’s Therapeutic Sales Market Share by Manufacturers
  • 3.1.3 Global Alzheimer’s Therapeutic Market Concentration Ratio (CR5 and HHI)
• 3.2 Alzheimer’s Therapeutic Revenue by Manufacturers
  • 3.2.1 Alzheimer’s Therapeutic Revenue by Manufacturers (2014-2019)
  • 3.2.2 Alzheimer’s Therapeutic Revenue Share by Manufacturers (2014-2019)
• 3.3 Alzheimer’s Therapeutic Price by Manufacturers
• 3.4 Alzheimer’s Therapeutic Manufacturing Base Distribution, Product Types
  • 3.4.1 Alzheimer’s Therapeutic Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Alzheimer’s Therapeutic Product Type
  • 3.4.3 Date of International Manufacturers Enter into Alzheimer’s Therapeutic Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Alzheimer’s Therapeutic Sales by Product
• 4.2 Global Alzheimer’s Therapeutic Revenue by Product
• 4.3 Alzheimer’s Therapeutic Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Alzheimer’s Therapeutic Breakdown Data by End User

6 North America

• 6.1 North America Alzheimer’s Therapeutic by Countries
  • 6.1.1 North America Alzheimer’s Therapeutic Sales by Countries
  • 6.1.2 North America Alzheimer’s Therapeutic Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Alzheimer’s Therapeutic by Product
• 6.3 North America Alzheimer’s Therapeutic by End User

7 Europe

• 7.1 Europe Alzheimer’s Therapeutic by Countries
  • 7.1.1 Europe Alzheimer’s Therapeutic Sales by Countries
  • 7.1.2 Europe Alzheimer’s Therapeutic Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Alzheimer’s Therapeutic by Product
• 7.3 Europe Alzheimer’s Therapeutic by End User

8 Asia Pacific

• 8.1 Asia Pacific Alzheimer’s Therapeutic by Countries
  • 8.1.1 Asia Pacific Alzheimer’s Therapeutic Sales by Countries
  • 8.1.2 Asia Pacific Alzheimer’s Therapeutic Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Alzheimer’s Therapeutic by Product
• 8.3 Asia Pacific Alzheimer’s Therapeutic by End User

9 Central & South America

• 9.1 Central & South America Alzheimer’s Therapeutic by Countries
  • 9.1.1 Central & South America Alzheimer’s Therapeutic Sales by Countries
  • 9.1.2 Central & South America Alzheimer’s Therapeutic Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Alzheimer’s Therapeutic by Product
• 9.3 Central & South America Alzheimer’s Therapeutic by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Alzheimer’s Therapeutic by Countries
  • 10.1.1 Middle East and Africa Alzheimer’s Therapeutic Sales by Countries
  • 10.1.2 Middle East and Africa Alzheimer’s Therapeutic Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Alzheimer’s Therapeutic by Product
• 10.3 Middle East and Africa Alzheimer’s Therapeutic by End User

11 Company Profiles

• 11.1 Pfizer Inc
  • 11.1.1 Pfizer Inc Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Pfizer Inc Alzheimer’s Therapeutic Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Pfizer Inc Alzheimer’s Therapeutic Products Offered
  • 11.1.5 Pfizer Inc Recent Development
• 11.2 Novartis International AG
  • 11.2.1 Novartis International AG Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Novartis International AG Alzheimer’s Therapeutic Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Novartis International AG Alzheimer’s Therapeutic Products Offered
  • 11.2.5 Novartis International AG Recent Development
• 11.3 Axovant Sciences Ltd
  • 11.3.1 Axovant Sciences Ltd Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Axovant Sciences Ltd Alzheimer’s Therapeutic Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Axovant Sciences Ltd Alzheimer’s Therapeutic Products Offered
  • 11.3.5 Axovant Sciences Ltd Recent Development
• 11.4 Acadia Pharmaceuticals, Inc
  • 11.4.1 Acadia Pharmaceuticals, Inc Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Acadia Pharmaceuticals, Inc Alzheimer’s Therapeutic Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Acadia Pharmaceuticals, Inc Alzheimer’s Therapeutic Products Offered
  • 11.4.5 Acadia Pharmaceuticals, Inc Recent Development
• 11.5 Biotie Therapies
  • 11.5.1 Biotie Therapies Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Biotie Therapies Alzheimer’s Therapeutic Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Biotie Therapies Alzheimer’s Therapeutic Products Offered
  • 11.5.5 Biotie Therapies Recent Development
• 11.6 Astra Zeneca plc
  • 11.6.1 Astra Zeneca plc Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Astra Zeneca plc Alzheimer’s Therapeutic Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Astra Zeneca plc Alzheimer’s Therapeutic Products Offered
  • 11.6.5 Astra Zeneca plc Recent Development
• 11.7 Eli Lilly, Inc
  • 11.7.1 Eli Lilly, Inc Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Eli Lilly, Inc Alzheimer’s Therapeutic Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Eli Lilly, Inc Alzheimer’s Therapeutic Products Offered
  • 11.7.5 Eli Lilly, Inc Recent Development
• 11.8 F. Hoffman Le Roche
  • 11.8.1 F. Hoffman Le Roche Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 F. Hoffman Le Roche Alzheimer’s Therapeutic Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 F. Hoffman Le Roche Alzheimer’s Therapeutic Products Offered
  • 11.8.5 F. Hoffman Le Roche Recent Development
• 11.9 Merck & Co
  • 11.9.1 Merck & Co Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Merck & Co Alzheimer’s Therapeutic Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Merck & Co Alzheimer’s Therapeutic Products Offered
  • 11.9.5 Merck & Co Recent Development
• 11.10 H. Lundbeck A/S
  • 11.10.1 H. Lundbeck A/S Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 H. Lundbeck A/S Alzheimer’s Therapeutic Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 H. Lundbeck A/S Alzheimer’s Therapeutic Products Offered
  • 11.10.5 H. Lundbeck A/S Recent Development
• 11.11 Takeda Pharmaceutical Company Ltd

12 Future Forecast

• 12.1 Alzheimer’s Therapeutic Market Forecast by Regions
  • 12.1.1 Global Alzheimer’s Therapeutic Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Alzheimer’s Therapeutic Revenue Forecast by Regions 2019-2025
• 12.2 Alzheimer’s Therapeutic Market Forecast by Product
  • 12.2.1 Global Alzheimer’s Therapeutic Sales Forecast by Product 2019-2025
  • 12.2.2 Global Alzheimer’s Therapeutic Revenue Forecast by Product 2019-2025
• 12.3 Alzheimer’s Therapeutic Market Forecast by End User
• 12.4 North America Alzheimer’s Therapeutic Forecast
• 12.5 Europe Alzheimer’s Therapeutic Forecast
• 12.6 Asia Pacific Alzheimer’s Therapeutic Forecast
• 12.7 Central & South America Alzheimer’s Therapeutic Forecast
• 12.8 Middle East and Africa Alzheimer’s Therapeutic Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Alzheimer’s Therapeutic Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

The global Alzheimer’s Therapeutic market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Alzheimer’s Therapeutic market based on company, product type, end user and key regions.

This report studies the global market size of Alzheimer’s Therapeutic in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Alzheimer’s Therapeutic in these regions.
This research report categorizes the global Alzheimer’s Therapeutic market by top players/brands, region, type and end user. This report also studies the global Alzheimer’s Therapeutic market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Pfizer Inc
Novartis International AG
Axovant Sciences Ltd
Acadia Pharmaceuticals, Inc
Biotie Therapies
Astra Zeneca plc
Eli Lilly, Inc
F. Hoffman Le Roche
Merck & Co
H. Lundbeck A/S
Takeda Pharmaceutical Company Ltd

Market size by Product
Memantine Hydrochloride
Donepezil Hydrochloride
Rivastigmine
Galantamine Hydrobromide
Market size by End User
Hospitals
Clinic
Other

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Alzheimer’s Therapeutic market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Alzheimer’s Therapeutic market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Alzheimer’s Therapeutic companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Alzheimer’s Therapeutic submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Alzheimer’s Therapeutic are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Alzheimer’s Therapeutic market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.